BioCentury | Apr 4, 2011
Company News

Myrexis cancer news

...restructuring to reduce annual expenses by $7.2 million. The company, which was formerly known as Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Company News

Myriad Pharmaceuticals cancer news

...Utah) in 2009, will change its name to Myrexis Inc. (see BioCentury, July 6, 2009). Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Finance

Regulatory milestones

...injectable biodegradable gel, is in Phase III testing to treat post-operative pain (see B3) . Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Clinical News

Azixa: Phase I/IIa data

...GBM. Myriad has exclusive rights to MPC-6827 from EpiCept. EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT), Tarrytown, N.Y. Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Clinical News

MPC-3100: Preliminary Phase I data

...6 patients. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Myriad Pharmaceuticals Inc....
BioCentury | Jun 8, 2010
Company News

Myriad Pharmaceuticals restructures

Myriad Pharmaceuticals Inc. (NASDAQ:MYRX) restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company suspended further development of its HIV program and plans to seek partners for...
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

...Merck & Co. Inc. did not disclose the development status of the HIV gp41 mimetics. Myriad Pharmaceuticals Inc.'s...
BioCentury | May 5, 2010
Financial News

Myriad misses Street

...before Dec. 31, 2010. Last year, Myriad Genetics spun out its drug development business into Myriad Pharmaceuticals Inc....
BioCentury | May 3, 2010
Clinical News

Myriad Pharmaceuticals preclinical data

...NamPRT) . Data were presented at the American Association for Cancer Research meeting in Washington. Myriad Pharmaceuticals Inc....
BioCentury | Apr 26, 2010
Company News

Javelin, Myriad Pharmaceuticals, Hospira deal

...shares outstanding on March 4 (see BioCentury, April 19). Javelin Pharmaceuticals Inc. (NYSE-A:JAV), Cambridge, Mass. Myriad Pharmaceuticals Inc....
Items per page:
1 - 10 of 53
BioCentury | Apr 4, 2011
Company News

Myrexis cancer news

...restructuring to reduce annual expenses by $7.2 million. The company, which was formerly known as Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Company News

Myriad Pharmaceuticals cancer news

...Utah) in 2009, will change its name to Myrexis Inc. (see BioCentury, July 6, 2009). Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Finance

Regulatory milestones

...injectable biodegradable gel, is in Phase III testing to treat post-operative pain (see B3) . Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Clinical News

Azixa: Phase I/IIa data

...GBM. Myriad has exclusive rights to MPC-6827 from EpiCept. EpiCept Corp. (NASDAQ:EPCT; SSE:EPCT), Tarrytown, N.Y. Myriad Pharmaceuticals Inc....
BioCentury | Jun 14, 2010
Clinical News

MPC-3100: Preliminary Phase I data

...6 patients. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Myriad Pharmaceuticals Inc....
BioCentury | Jun 8, 2010
Company News

Myriad Pharmaceuticals restructures

Myriad Pharmaceuticals Inc. (NASDAQ:MYRX) restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company suspended further development of its HIV program and plans to seek partners for...
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

...Merck & Co. Inc. did not disclose the development status of the HIV gp41 mimetics. Myriad Pharmaceuticals Inc.'s...
BioCentury | May 5, 2010
Financial News

Myriad misses Street

...before Dec. 31, 2010. Last year, Myriad Genetics spun out its drug development business into Myriad Pharmaceuticals Inc....
BioCentury | May 3, 2010
Clinical News

Myriad Pharmaceuticals preclinical data

...NamPRT) . Data were presented at the American Association for Cancer Research meeting in Washington. Myriad Pharmaceuticals Inc....
BioCentury | Apr 26, 2010
Company News

Javelin, Myriad Pharmaceuticals, Hospira deal

...shares outstanding on March 4 (see BioCentury, April 19). Javelin Pharmaceuticals Inc. (NYSE-A:JAV), Cambridge, Mass. Myriad Pharmaceuticals Inc....
Items per page:
1 - 10 of 53